The 350,000-share equity plan increase was approved despite material opposition (14% votes against, 16% broker non-votes), but the outcome was widely expected after ISS objected. The 200,000-share ESPP expansion indicates management's desire to broaden employee equity participation. Monitor for issuance of new equity awards under the refreshed share pool, but no immediate trading catalyst.
Price Chart
Executive Summary
Anika Therapeutics held its 2026 Annual Meeting on June 18, 2026. Stockholders approved an amendment to the 2017 Omnibus Incentive Plan (the 'Revised Seventh Amended Plan') increasing the share reserve by 350,000 shares to 6,110,000 shares, and an amendment to the 2021 Employee Stock Purchase Plan doubling its share reserve from 200,000 to 400,000 shares. Three incumbent directors (Fischetti, Henneman, Griffin) were re-elected. This is a routine post-meeting administrative filing reflecting shareholder approval of previously disclosed equity plan increases.
Key Facts
- Stockholders approved the Revised Seventh Amended Plan, increasing authorized shares under the 2017 Omnibus Incentive Plan from 5,760,000 to 6,110,000 (a 350,000-share increase).
- Stockholders approved the ESPP Amendment, doubling the share reserve under the 2021 Employee Stock Purchase Plan from 200,000 to 400,000 shares.
- All three director nominees (Gary P. Fischetti, John B. Henneman III, Stephen D. Griffin) were elected with strong majorities (For votes ranging from 8.8M to 9.3M, against 56K-537K).
- Proposal 4 (equity plan) passed with approximately 8.0M For vs 1.3M Against, with 1.8M broker non-votes — notable opposition but approved.
- Proposal 5 (ESPP) passed with approximately 9.1M For vs 257K Against — strong support.
- No unexpected departures or appointments of directors or officers; all changes relate to equity plan amendments tied to the annual meeting vote.
Financial Impact
Equity plan share increases allow for ongoing employee and director equity compensation. The 350,000-share increase to the 2017 Plan represents potential future dilution of ~2.6% based on 13,305,624 shares outstanding. The ESPP increase adds capacity for ~3.0% potential dilution. No immediate financial impact from these administrative approvals.
Risk Factors
- Increased share reserve enables potential dilution of up to ~2.6% from the 2017 Plan and ~3.0% from the ESPP when fully utilized.
- Opposition to the equity plan (1.3M Against) suggests some shareholder discontent with dilution levels.
- No financial results disclosed in this filing — the absence of operational data limits directional read-through.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-004253 |
| Exhibit: exh_102.htm | 0001171843-26-004253 |
| Document: f8k_062326.htm | 0001171843-26-004253 |
| Document: 0001171843-26-004253-index-headers.html | 0001171843-26-004253 |
| Document: 0001171843-26-004253-index.html | 0001171843-26-004253 |
| Document: 0001171843-26-004253.txt | 0001171843-26-004253 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 8-K | $16.17 $21.68 | ▲ +34.08% | ▲ +29.06% | $19.10 (+18.12%) |
Jul 14, 2026 11w ago | 8-K | $15.93 $22.03 | ▲ +38.29% | ▲ +35.95% | $19.10 (+19.90%) |
Jun 23, 2026 14w ago | 8-K | $14.73 $15.01 | ▲ +1.90% | ▼ −0.03% | $19.10 (+29.67%) |
Jun 11, 2026 16w ago | Institutional Cluster | $14.72 $15.60 | ▼ −5.98% | ▼ −4.20% | $19.10 (−29.76%) |
Jun 8, 2026 16w ago | DEFA14A | $14.60 $16.03 | ▲ +9.79% | ▲ +8.16% | $19.10 (+30.82%) |
Jun 1, 2026 17w ago | DEFA14A | $14.63 $14.63 | · 0.00% | ▲ +1.30% | $19.10 (+30.55%) |
Apr 30, 2026 22w ago | Insider Cluster | $12.45 $14.90 | ▲ +19.68% | ▲ +14.71% | $19.10 (+53.41%) |
Apr 29, 2026 22w ago | 8-K | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 28, 2026 22w ago | DEFA14A | $12.39 $14.90 | ▲ +20.26% | ▲ +14.21% | $19.10 (+54.16%) |
Apr 15, 2026 24w ago | Press Release | $15.39 $14.80 | ▼ −3.83% | ▼ −9.65% | $19.10 (+24.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access